Drugs@FDA: FDA-Approved Drugs
New Drug Application (NDA): 021641
Company: TEVA
Company: TEVA
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
AZILECT | RASAGILINE MESYLATE | EQ 0.5MG BASE | TABLET;ORAL | Prescription | AB | Yes | No |
AZILECT | RASAGILINE MESYLATE | EQ 1MG BASE | TABLET;ORAL | Prescription | AB | Yes | Yes |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
05/16/2006 | ORIG-1 | Approval | Type 1 - New Molecular Entity | STANDARD |
Label (PDF)
Letter (PDF) Review |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021641lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/021641s000LTR.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021641s000_AzilectTOC.cfm |
Supplements
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
---|---|---|---|---|---|
06/16/2020 | SUPPL-21 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021641s021lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/021641Orig1s021ltr.pdf | |
12/20/2018 | SUPPL-20 | Labeling-Package Insert |
Label (PDF)
|
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021641s020lbl.pdf | |
12/09/2015 | SUPPL-19 | Manufacturing (CMC) |
Label is not available on this site. |
||
07/20/2015 | SUPPL-18 | Manufacturing (CMC) |
Label is not available on this site. |
||
05/29/2014 | SUPPL-17 | Efficacy-New Indication |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021641s016s017lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/021641Orig2s016,s017ltr.pdf | |
05/29/2014 | SUPPL-16 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021641s016s017lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/021641Orig2s016,s017ltr.pdf | |
12/09/2009 | SUPPL-10 | Labeling |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021641s002s003s004s005s006s007s008s010ltr.pdf | |
12/09/2009 | SUPPL-8 | Efficacy-Labeling Change With Clinical Data |
Label (PDF)
Letter (PDF) Review Summary Review (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021641s002s003s004s005s006s007s008s010ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021641S008TOC.cfm https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021641S008_SumR.pdf | |
12/09/2009 | SUPPL-7 | Labeling |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021641s002s003s004s005s006s007s008s010ltr.pdf | |
12/09/2009 | SUPPL-5 | Labeling |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021641s002s003s004s005s006s007s008s010ltr.pdf | |
12/09/2009 | SUPPL-4 | Labeling |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021641s002s003s004s005s006s007s008s010ltr.pdf | |
12/09/2009 | SUPPL-3 | Labeling |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021641s002s003s004s005s006s007s008s010ltr.pdf | |
12/09/2009 | SUPPL-2 | Labeling |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021641s002s003s004s005s006s007s008s010ltr.pdf |
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
---|---|---|---|---|---|
06/16/2020 | SUPPL-21 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021641s021lbl.pdf | |
12/20/2018 | SUPPL-20 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021641s020lbl.pdf | |
05/29/2014 | SUPPL-17 | Efficacy-New Indication | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021641s016s017lbl.pdf | |
05/29/2014 | SUPPL-16 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021641s016s017lbl.pdf | |
12/09/2009 | SUPPL-10 | Labeling | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf | |
12/09/2009 | SUPPL-8 | Efficacy-Labeling Change With Clinical Data | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf | |
12/09/2009 | SUPPL-7 | Labeling | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf | |
12/09/2009 | SUPPL-5 | Labeling | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf | |
12/09/2009 | SUPPL-4 | Labeling | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf | |
12/09/2009 | SUPPL-3 | Labeling | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf | |
12/09/2009 | SUPPL-2 | Labeling | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf | |
05/16/2006 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021641lbl.pdf |
AZILECT
TABLET;ORAL; EQ 0.5MG BASE
TE Code = AB
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | RLD | TE Code | Application No. | Company |
---|---|---|---|---|---|---|---|---|
AZILECT | RASAGILINE MESYLATE | EQ 0.5MG BASE | TABLET;ORAL | Prescription | Yes | AB | 021641 | TEVA |
RASAGILINE MESYLATE | RASAGILINE MESYLATE | EQ 0.5MG BASE | TABLET;ORAL | Prescription | No | AB | 201889 | ALKEM LABS LTD |
RASAGILINE MESYLATE | RASAGILINE MESYLATE | EQ 0.5MG BASE | TABLET;ORAL | Prescription | No | AB | 201971 | AUROBINDO PHARMA USA |
RASAGILINE MESYLATE | RASAGILINE MESYLATE | EQ 0.5MG BASE | TABLET;ORAL | Prescription | No | AB | 201892 | CHARTWELL RX |
RASAGILINE MESYLATE | RASAGILINE MESYLATE | EQ 0.5MG BASE | TABLET;ORAL | Prescription | No | AB | 206153 | INDOCO |
RASAGILINE MESYLATE | RASAGILINE MESYLATE | EQ 0.5MG BASE | TABLET;ORAL | Prescription | No | AB | 207004 | MICRO LABS |
RASAGILINE MESYLATE | RASAGILINE MESYLATE | EQ 0.5MG BASE | TABLET;ORAL | Prescription | No | AB | 201970 | ORBION PHARMS |
RASAGILINE MESYLATE | RASAGILINE MESYLATE | EQ 0.5MG BASE | TABLET;ORAL | Prescription | No | AB | 218163 | SKG PHARMA |
TABLET;ORAL; EQ 1MG BASE
TE Code = AB
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | RLD | TE Code | Application No. | Company |
---|---|---|---|---|---|---|---|---|
AZILECT | RASAGILINE MESYLATE | EQ 1MG BASE | TABLET;ORAL | Prescription | Yes | AB | 021641 | TEVA |
RASAGILINE MESYLATE | RASAGILINE MESYLATE | EQ 1MG BASE | TABLET;ORAL | Prescription | No | AB | 201889 | ALKEM LABS LTD |
RASAGILINE MESYLATE | RASAGILINE MESYLATE | EQ 1MG BASE | TABLET;ORAL | Prescription | No | AB | 201971 | AUROBINDO PHARMA USA |
RASAGILINE MESYLATE | RASAGILINE MESYLATE | EQ 1MG BASE | TABLET;ORAL | Prescription | No | AB | 201892 | CHARTWELL RX |
RASAGILINE MESYLATE | RASAGILINE MESYLATE | EQ 1MG BASE | TABLET;ORAL | Prescription | No | AB | 206153 | INDOCO |
RASAGILINE MESYLATE | RASAGILINE MESYLATE | EQ 1MG BASE | TABLET;ORAL | Prescription | No | AB | 207004 | MICRO LABS |
RASAGILINE MESYLATE | RASAGILINE MESYLATE | EQ 1MG BASE | TABLET;ORAL | Prescription | No | AB | 201970 | ORBION PHARMS |
RASAGILINE MESYLATE | RASAGILINE MESYLATE | EQ 1MG BASE | TABLET;ORAL | Prescription | No | AB | 218163 | SKG PHARMA |